NY-ALEPH-FARMS
6.10.2022 14:01:50 CEST | Business Wire | Press release
Aleph Farms, the first cultivated meat company to grow steaks directly from non-genetically engineered animal cells, today announced the addition of Kevin Benmoussa as its Executive VP and Chief Financial Officer. He joins the C-Level leadership team of Didier Toubia (co-founder and CEO), Dr. Neta Lavon (CTO and VP R&D), Prof. Shulamit Levenberg (co-founder and Chief Scientific Adviser) and Yifat Gavriel (Chief Regulatory Affairs, QA and Product Safety). Based in Aleph Farms’ first US headquarters in New York City's historic Meatpacking District, Benmoussa will lead the company’s global growth agenda, spearhead its operational expansion in the US, and oversee finance, administration and legal departments globally for the company.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221006005101/en/
Kevin Benmoussa, CFO, Aleph Farms (Photo: Business Wire)
“Kevin is a veteran of the food and beverage industry, and brings invaluable expertise in defining and executing winning strategies for achieving growth and profitability,” said Didier Toubia, CEO and co-founder of Aleph Farms. “Kevin joins at an exciting time for Aleph Farms as we look to establish a new category of animal products by gaining regulatory approvals, scaling our production and driving consumer acceptance.”
Kevin Benmoussa was previously Chief Financial Officer at The Vita Coco Company, where he was responsible for expanding the company’s global finance functions before leading the company’s initial public offering in 2021. Prior to that, he held numerous corporate leadership positions at Nestlé Waters North America, Inc. and PepsiCo Inc. where he drove growth and profitability through M&A, strategic alliances and business development.
“Aleph Farms is at an inflection point and has promising potential to significantly optimize the way we approach the production of animal-based products by improving sustainability, food security, and animal welfare conditions in our food systems,” said Mr. Benmoussa. “I am extremely excited to join Didier and his team, and help drive this transformation from our new US offices.”
Aleph Farms is working closely with regulatory agencies around the world as it prepares for the commercial launch of its first product, a cultivated thin-cut beef steak. The company also plans to produce different cuts of steaks as well as cultivated collagen through additional proprietary capabilities. In all cases, Aleph Farms’ products are produced from cells that are isolated from a living cow and not immortalized or genetically modified, avoiding slaughter and part of an inclusive solution for a sustainable and secure meat sector.
About Aleph Farms
Aleph Farms grows cultivated beef steaks from cells that are isolated from a living cow and not immortalized or genetically modified, avoiding slaughter and achieving reduced environmental impact. The company was co-founded in 2017 by Didier Toubia, The Kitchen Hub by Strauss Group, and Professor Shulamit Levenberg of the Technion - Israel Institute of Technology. Its vision is to ensure unconditional nutrition for anyone, anytime, anywhere. For more information, follow Aleph Farms on Instagram, Twitter, Facebook or LinkedIn or visit www.aleph-farms.com. Access the Aleph Farms press kit here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221006005101/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Okomera Announces a Commercial Agreement With Servier to Use Its Tumor Miniaturization Technology for Cancer Research21.10.2026 08:00:00 CEST | Press release
Okomera reaches a key milestone in its industrial rollout with the first commercial installation of its integrated platform, combining hardware, software and biology, in the laboratories of an international pharmaceutical group. Servier will use Okomera’s technology to evaluate new therapeutic approaches in oncology and immuno-oncology. Okomera, a TechBio company pioneering personalized cancer care through a proprietary technology platform combining tumor mini-avatars, microfluidics, and AI-powered imaging, today announced the signing of a commercial agreement with Servier, an independent international pharmaceutical group, to use its technology in the development of new cancer treatments. With more than 90% of oncology drug candidates never reaching the market, identifying early on the therapeutic approaches most likely to succeed is a critical challenge for the pharmaceutical industry. Okomera’s technology helps precisely reduce this attrition, by steering development toward candidat
Bureau Veritas: Double Digit Total Revenue Growth in the Third Quarter of 202621.10.2026 07:30:00 CEST | Press release
Organic revenue growth sequential improvement;2026 outlook confirmed Bureau Veritas (BOURSE:BVI): The execution of LEAP | 28 has transformed Bureau Veritas into a more focused, faster-growing and higher-performing multi-specialist company. Its Product Line-centric operating model combines the Company’s global scale and resilience with clear priorities, stronger accountability and deep specialist expertise. This creates a more repeatable growth model, enabling faster execution, stronger capabilities and higher conversion of growth into profitability. Q3 2026 Key figures1 › New reporting structure effective July 1st, 2026, comprising four divisions: Industrials & Commodities, Buildings & Infrastructure, Business Assurance, and Product Testing & Services, excluding the planned for exit businesses of Oil & Petrochemicals and Coal Testing and Inspection, and “Government Services”; › Revenue of EUR 1,569.7 million, up 10.1% year-on-year and up 6.2% organically; • Positive scope effect of 1.8
AI Emerges as CEOs' Most Critical Challenge, Egon Zehnder Study Finds21.10.2026 07:00:00 CEST | Press release
Third annual edition of The CEO Response finds leaders prioritizing AI and business alliances as demands on CEO leadership grow Artificial intelligence has emerged as the most critical challenge facing CEOs worldwide, ahead of geopolitical instability and economic uncertainty, according to The CEO Response, Egon Zehnder's third annual study of 843 global chief executives. Nearly half of CEOs (48%) consider the adoption and impact of AI an extremely critical challenge, up from 37% in 2025. Geopolitical instability (44%) and economic uncertainty (40%) follow, while 62% expect geopolitical disruption to increase over the next 12 months. These challenges are shaping where CEOs are focusing their efforts. Half (50%) identify AI investment among the three most important changes they're making to their organizations, followed by innovation (48%) and improving their cost base (41%). By comparison, 29% selected upskilling and talent development as a top priority. “CEOs can invest in AI much fas
AMWC Dubai 2026: Galderma Reinforces Its Injectable Aesthetics Leadership21.10.2026 07:00:00 CEST | Press release
Galderma will present eight posters spanning its full Injectable Aesthetics portfolio at AMWC Dubai 2026, highlighting the complementary benefits of Sculptra® and Restylane®, and pooled phase III study data for Relfydess® (relabotulinumtoxinA)1-8 With 30 years of innovation, Restylane continues to evolve through the development of new technologies and expanded clinical indications, with data to be presented from four studies across the chin, jawline, temples, and lower face Several Meet-the-Expert sessions and a symposium on the AART™ of Body, which highlights new expanded indications for Sculptra in the gluteal area, posterior thighs, and décolletage, follows Sculptra’s recent approval for use on the body in the United Arab Emirates (UAE)9 Galderma (SIX: GALD) will showcase data from its leading innovative Injectable Aesthetics portfolio at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) taking place in Dubai, United Arab Emirates (UAE), from October 21-23, 2026. The company
Sihoo præsenterer næste generation af ergonomiske kontorløsninger på ORGATEC 202620.10.2026 20:12:00 CEST | Pressemeddelelse
Med ORGATEC 2026 lige om hjørnet vil Sihoo, specialist i ergonomiske sidde løsninger, præsentere sine næste generations løsninger til arbejdspladsen i hal 8.1, stand A-060 og B-061. I tråd med messens tema, »Fra rum til relationer: design af rum i en verden i konstant forandring«, vil Sihoo demonstrere, hvordan adaptivt ergonomisk design understøtter skiftende siddestillinger og nye behov på moderne arbejdspladser. Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20261020048673/da/ Sihoo på ORGATEC 2026 i Köln En oplevelseszone baseret på forskellige arbejdsscenarier Sihoos stand har et åbent layout, hvor en orange-hvid farvepalet kombineres med loftskonstruktioner i flere niveauer, halvgennemsigtige skillevægge og integreret belysning. Arbejdsstationer med højdejusterbare skriveborde og skærme samt siddeområder til samarbejde genskaber velkendte kontormiljøer og viser, hvordan ergonomiske stole passer ind på moderne arbejdspl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
